DKD-C Resources

Centers for Disease Control (CDC) 1 link

• Kidney Disease Surveillance System

Healthy People 2030 1 link

• Chronic Kidney Disease

United States Renal Data System (USRDS) 10 links

• US Kidney Disease Statistics
• 2023 Interactive Annual Data Report
• 2022 Interactive Annual Data Report
• 2021 Interactive Annual Data Report
• 2020 Interactive Annual Data Report
• US Renal Data System 2023
• US Renal Data System 2022
• US Renal Data System 2021
• US Renal Data System 2020
• US Renal Data System 2019

General DKD Information 10 links

• Diabetic Kidney Disease: Challenges, Progress, and Possibilities
• The Global Epidemiology of Diabetes and Kidney Disease
• Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease
• Preserving Kidney Function Instead of Replacing It
• Implications of Specialist Density for Diabetes Care in the United States
• Cardio-Renal-Metabolic Care Models Toward Achieving Effective Interdisciplinary Care
• Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
• Health Care Access and Use Among Adults with Diabetes During the COVID-19 Pandemic — United States, February–March 2021
• Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria

Complications of DKD 4 links

• Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
• Global trends in diabetes complications: A review of current evidence
• Changes in Diabetes-Related Complications in the United States, 1990–2010
• Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results From the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database

Outcomes and Data Associated with DKD 9 links

• Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
• Centers for Disease Control and Prevention: National Diabetes Statistics Report
• International Diabetes Federation: IDF Diabetes Atlas, 9th Ed
• Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
• Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
• Heart Disease and Stroke Statistics—2021 Update
• Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children An Analysis of the CURE-CKD Registry
• Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease among American Indians/Alaska Natives — United States, 1996–2013
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials.

Medications Associated with DKD 17 links

• Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria
• Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States
• Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
• Dapagliflozin in Patients with Chronic Kidney Disease
• Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
• Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
• Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
• Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial
• Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study
• Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease
• Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
• Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence
• Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: Findings based on the EMPA-REG OUTCOME Trial
• The Medical Letter: Comparison Chart: Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
• In the Years Before the COVID-19 Pandemic, Nearly 13 Million Adults Delayed or Did Not Get Needed Prescription Drugs Because of Costs
• Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol

DKD and the Pediatric Population 2 links

• Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017
• Prevalence of Hypertension and Albuminuria in Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis

DKD Payment and Drug Pricing 3 links

• RAND Health Care: Value-Based Payment and Health Care System Preparedness and Resilience
• Framework For Specialty Value Transformation: Perspectives From A Commercial Payer
• Contributor: A More Nuanced View of Dialysis Providers “Gaming the Rules”

DKD and Diversity/Equality 6 links

• Reported Racial Discrimination, Trust in Physicians, and Medication Adherence Among Inner-City African Americans With Hypertension
• Beyond Consent: Building Trusting Relationships with Diverse Populations in Precision Medicine Research
• Effects of Community-Based Health Worker Interventions to Improve Chronic Disease Management and Care Among Vulnerable Populations: A Systematic Review
• A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
• New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race
• Time to Eliminate Health Care Disparities in the Estimation of Kidney Function

Implementing New Diabetic Kidney Disease Treatments – Time to Act 4 links

• Recording
• Agenda
• Slides
• Bios

Implementing New Diabetic Kidney Disease Treatments – Time to Act 3 links

• Recording
• Slides
• Bios

Implementing New Diabetic Kidney Disease Treatments – Time for Nephrologists to Act 2 links

• Agenda
• Slides

Management of Diabetes & Kidney Disease through COVID-19 4 links

• Recording
• Slides
• Bios
• Why Should I Join A Clinical Trail?

Goal-Directed Medical Therapies (GDMT) for Patients with Diabetic Kidney Disease and Beyond 3 links

• Recording
• Slides
• Bios

New Approaches to Transform Outcomes for Kidney Disease and Heart Disease in Patients with Diabetes 3 links

• Recording
• Slides
• Bios